Literature DB >> 32432141

Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: Associations with abdominal pain, visceral hypersensitivity and psychological performance.

Geng Qin1, Yu Zhang1, Shu-Kun Yao2.   

Abstract

BACKGROUND: Visceral hypersensitivity and psychological performance are the main pathophysiological mechanisms of irritable bowel syndrome (IBS). Previous studies have found that cholecystokinin (CCK) can enhance colon movement and that serotonin transporter (SERT) is a transmembrane transport protein with high affinity for 5-hydroxytryptamine, which can rapidly reuptake 5-hydroxytryptamine and then regulate its action time and intensity. We speculate that SERT and CCK might play a role in the pathogenesis of diarrhea-predominant IBS (IBS-D) by affecting visceral sensitivity and the brain-gut axis. AIM: To determine SERT and CCK levels in IBS-D patients diagnosed using Rome IV criteria and to analyze their associations with abdominal pain, visceral hypersensitivity and psychological performance.
METHODS: This study collected data from 40 patients with IBS-D at the China-Japan Friendship Hospital from September 2017 to April 2018 and 18 healthy controls. The severity of abdominal pain, visceral sensitivity and psychological performance were evaluated in IBS-D patients and healthy controls, the levels of SERT and CCK in plasma and colonic mucosa were evaluated, and the correlations between them were analyzed.
RESULTS: There were significant differences in the initial sensation threshold (31.00 ± 8.41 mL vs 52.22 ± 8.09 mL, P < 0.001), defecating sensation threshold (51.75 ± 13.57 mL vs 89.44 ± 8.73 mL, P < 0.001) and maximum tolerable threshold (97.25 ± 23.64 mL vs 171.11 ± 20.83 mL, P < 0.001) between the two groups. IBS-D patients had more severe anxiety (7.78 ± 2.62 vs 2.89 ± 1.02, P < 0.001) and depressive (6.38 ± 2.43 vs 2.06 ± 0.73, P < 0.001) symptoms than healthy controls. Significant differences were also found in mucosal CCK (2.29 ± 0.30 vs 1.66 ± 0.17, P < 0.001) and SERT (1.90 ± 0.51 vs 3.03 ± 0.23, P < 0.001) between the two groups. There was a significant positive correlation between pain scores and mucosal CCK (r = 0.96, 0.93, 0.94, P < 0.001). Significant negative correlations between anxiety (r = -0.98; P < 0.001), depression (r = -0.99; P < 0.001), pain evaluation (r = -0.96, -0.93, -0.95, P < 0.001) and mucosal SERT were observed.
CONCLUSION: IBS-D patients had psychosomatic disorders and visceral hypersensitivity. SERT and CCK might be involved in the pathogenesis of IBS-D by regulating the brain-gut axis and affecting visceral sensitivity. This provides a new potential method for identifying a more specific and effective therapeutic target. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Abdominal pain; Cholecystokinin; Irritable bowel syndrome; Psychological performance; Serotonin transporter; Visceral hypersensitivity

Year:  2020        PMID: 32432141      PMCID: PMC7211531          DOI: 10.12998/wjcc.v8.i9.1632

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  32 in total

1.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

Review 2.  Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV.

Authors:  Vincenzo Stanghellini
Journal:  Dig Dis       Date:  2018-02-08       Impact factor: 2.404

Review 3.  Gene, environment, and brain-gut interactions in irritable bowel syndrome.

Authors:  Shin Fukudo; Motoyori Kanazawa
Journal:  J Gastroenterol Hepatol       Date:  2011-04       Impact factor: 4.029

Review 4.  Heterogeneity of enterochromaffin cells within the gastrointestinal tract.

Authors:  S Diwakarla; L J Fothergill; J Fakhry; B Callaghan; J B Furness
Journal:  Neurogastroenterol Motil       Date:  2017-06       Impact factor: 3.598

Review 5.  Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.

Authors:  Gary M Mawe; Jill M Hoffman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-25       Impact factor: 46.802

6.  Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis.

Authors:  Mira M Wouters; Sander Van Wanrooy; Anh Nguyen; James Dooley; Javier Aguilera-Lizarraga; Winde Van Brabant; Josselyn E Garcia-Perez; Lukas Van Oudenhove; Marc Van Ranst; Jan Verhaegen; Adrian Liston; Guy Boeckxstaens
Journal:  Gut       Date:  2015-06-12       Impact factor: 23.059

7.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

8.  Distribution and characterisation of CCK containing enteroendocrine cells of the mouse small and large intestine.

Authors:  Josiane Fakhry; Joyce Wang; Patricia Martins; Linda J Fothergill; Billie Hunne; Pierre Prieur; Arthur Shulkes; Jens F Rehfeld; Brid Callaghan; John B Furness
Journal:  Cell Tissue Res       Date:  2017-04-17       Impact factor: 5.249

Review 9.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

Authors:  Ingvar Bjelland; Alv A Dahl; Tone Tangen Haug; Dag Neckelmann
Journal:  J Psychosom Res       Date:  2002-02       Impact factor: 3.006

10.  Relationships of abdominal pain, reports to visceral and temperature pain sensitivity, conditioned pain modulation, and heart rate variability in irritable bowel syndrome.

Authors:  M E Jarrett; C J Han; K C Cain; R L Burr; R J Shulman; P G Barney; B D Naliboff; J Zia; M M Heitkemper
Journal:  Neurogastroenterol Motil       Date:  2016-03-19       Impact factor: 3.598

View more
  2 in total

1.  The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis.

Authors:  Zhichao Hu; Meixuan Li; Liang Yao; Yinshu Wang; Enkang Wang; Jianye Yuan; Fengyun Wang; Kehu Yang; Zhaoxiang Bian; Linda L D Zhong
Journal:  BMC Gastroenterol       Date:  2021-01-07       Impact factor: 3.067

2.  Exploring the role of neurogenic pathway-linked cholecystokinin release in remote preconditioning-induced cardioprotection.

Authors:  Huilian Li; Cuilan An
Journal:  Acta Cir Bras       Date:  2020-10-30       Impact factor: 1.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.